New ALS drug stabilizes decline with a trend toward improved strength, mobility for some (IMAGE)

WashU Medicine

New ALS drug stabilizes decline with a trend toward improved strength, mobility for some

Caption

WashU Medicine researchers Robert Bucelli, MD, PhD, (left) and Timothy M. Miller, MD, PhD, co-lead WashU Medicine’s ALS Center, where they lead ongoing clinical trials investigating the FDA-approved drug tofersen for treatment of a rare form of ALS. Their latest study finds some study participants experienced delayed symptom progression and death; a subset even made gains in function.

Credit

Huy Mach

Usage Restrictions

This image is to be used in accordance with the mission, policies and guidelines of Washington University in St. Louis. Visit https://wustl.edu/about/compliance-policies/media-policies/multimedia- use/ for more information.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.